Menu

Topics

Connect

Comments

Want to discuss? Please read our Commenting Policy first.

Spartan Bioscience seeks creditor protection after COVID-19 rapid test issue arises

WATCH: COVID-19: Canadian biotech company recalls rapid test kits – May 3, 2020

The Canadian maker of a rapid COVID-19 test has filed for creditor protection after pausing shipments of the product due to a recently identified issue with the system.

Story continues below advertisement

Spartan Bioscience Inc. says the problem is not a safety issue.

The Ottawa-based company says it’s seeking protection from creditors while it restructures its operations and refines the test’s performance.

Spartan says it’s laying off 60 employees, or around 70 per cent of its workforce.

The latest health and medical news emailed to you every Sunday.

Despite the challenges, Spartan says it remains committed to mobile DNA-testing technology in the fight against COVID-19.

It says Health Canada’s authorization remains in place while Spartan works with the agency to resolve the issue.

Interim CEO Jennifer Ross-Carriere said Spartan Bioscience is a Canadian company working to protect the health and safety of all Canadians.

Story continues below advertisement

“We believe Canada needs more innovation in the biosciences sector and we are incredibly proud of our team for quickly designing and manufacturing the only made-in-Canada rapid diagnostic PCR COVID-19 test,” Ross-Carriere wrote in an email.

Advertisement

You are viewing an Accelerated Mobile Webpage.

View Original Article